Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

A coalition of healthcare advocacy community organizations gathered outside Pfizer Worldwide Headquarters in Manhattan on March 11, 2021.

A coalition of healthcare advocacy community organizations gathered outside Pfizer Worldwide Headquarters in Manhattan on March 11, 2021. (Photo: Erik McGregor/LightRocket via Getty Images)

Coalition Calls on Biden to Use US-Owned Patent to Share Covid Vaccine With the World

"The U.S. government can help end the pandemic if it uses its legal leverage with Moderna to jumpstart an ambitious vaccine manufacturing program to benefit the world."

Jake Johnson

Public health advocacy groups and scientists are pressuring the Biden administration to use the U.S. government's ownership of a key patent as leverage to ensure that the coronavirus vaccine co-developed by Moderna and National Institutes of Health is widely produced and distributed around the world, particularly in developing countries.

"The U.S. government has an embarrassing history of giving away publicly-funded and publicly-owned medical technology to corporations, which then ration it back to the people at monopoly prices."
—Peter Maybarduk, Public Citizen

The patent in question covers crucial spike-protein technology developed by the NIH, an invention that has since been utilized in at least five major Covid vaccines—including the Moderna-NIH shot formally known as mRNA-1273.

In a letter (pdf) earlier this week to Health and Human Services Secretary Xavier Becerra, NIH Director Francis Collins, and National Institute of Allergy and Infectious Disease Director Anthony Fauci, a coalition of advocacy groups led by PrEP4All and around a dozen scientists said the government-owned patent should be used as a "tool" to "facilitate scale-up of production of mRNA-1273 and ensure rapid, equitable global access."

"The U.S. government has not licensed the patent to Moderna. It is imperative that the NIH uses any licensing agreement to include provisions to help increase global access to this lifesaving technology, rather than just a monetary royalty," the letter reads. "U.S. taxpayers have invested over $2.5 billion in the development of mRNA-1273. Now it is time for our government to ensure that this critical lifesaving technology be made available to all. This could contribute to saving millions of lives globally."

The new demand comes as the United States and other rich nations continue to block an India and South Africa-led push to temporarily waive certain international patent protections in order to expand access to coronavirus vaccines in countries currently struggling to administer a single shot.

In their letter on Wednesday, the public health organizations urged the U.S. government to use its leverage to negotiate patent licensing terms that "require technology sharing with the World Health Organization to help ramp up global production" and guarantee widespread distribution of the vaccine at a low cost.

As the New York Times reported earlier this week, the WHO "created a technology pool last year to encourage companies to share know-how with manufacturers in lower-income nations. Not a single vaccine company has signed up."

"The problem is that the companies don't want to do it," James Love, head of the nonprofit Knowledge Ecology International, told the Times. "And the government is just not very tough with the companies."

Peter Maybarduk, director of the Access to Medicines program at Public Citizen, lamented in a statement that "the U.S. government has an embarrassing history of giving away publicly-funded and publicly-owned medical technology to corporations, which then ration it back to the people at monopoly prices."

"The U.S. government can help end the pandemic if it uses its legal leverage with Moderna to jumpstart an ambitious vaccine manufacturing program to benefit the world," Maybarduk said. "We must do better. Many lives are at stake."

Read the full letter:

Dear Secretary Becerra, Dr. Collins, and Dr. Fauci:

We write about the soon-to-issue-patent, U.S. Patent No. 10,960,070 ("the '070 patent"), that protects the use of proline-substituted coronavirus spike proteins stabilized in their prefusion conformation as a vaccine immunogen. The mRNA-1273 vaccine, co-developed by NIAID and Moderna, utilizes this technology for its immunogen. The '070 patent is owned by the United States Government, reflecting the critical contributions that NIAID and NIH made to the invention of this technology.

This government-owned patent is an important policy tool that the U.S. government could use to facilitate scale-up of production of mRNA-1273 and ensure rapid, equitable global access. Currently, at best, only one billion doses of mRNA-1273 will be produced in 2021, far short of global demand.

The U.S. government has not licensed the patent to Moderna. It is imperative that the NIH uses any licensing agreement to include provisions to help increase global access to this lifesaving technology, rather than just a monetary royalty.

Specifically, the licensing agreement should:

1. Empower the U.S. government to authorize manufacturing of mRNA-1273—including by government-owned production facilities.

Currently, Moderna has only contracted with a single contract manufacturing organization (CMO), Lonza Group AG, to produce drug substance for mRNA-1273. By contracting with other CMOs to produce drug substance and help perform other manufacturing steps, more doses of mRNA-1273 could be produced. Such provisions should include the ability for the U.S. government to compel transfer of know-how from Moderna to other CMOs to facilitate scale up for all production steps of the manufacturing process.

2. Require technology sharing with the World Health Organization to help ramp up global production.

The Director-General of the World Health Organization has urged countries to share vaccine technology and know-how openly to help build global manufacturing capacity. Moderna has so far ignored requests from developing country manufacturers to share technology. Requiring Moderna to work with the WHO's COVID-19 technology access pool can help unlock additional production.

3. Include requirements for accessible pricing universally.

Moderna is currently charging between US$10 and US$40 a dose for mRNA-12738, despite it costing less than $3 a dose to manufacture. This high price, coupled with Moderna's lack of planned market entry for many low-and middle-income countries, may prevent those most in need from accessing mRNA-1273. Licensing the '070 patent gives the U.S. government leverage to increase global access by requiring accessible pricing to mRNA-1273.

Assertion of U.S. government-owned intellectual property to increase access to pharmaceutical products is not unprecedented. In 2019, the federal government sued Gilead Sciences for its infringement of government owned patents protecting the use of Truvada and Descovy for HIV pre-exposure prophylaxis (PrEP)—and per the complaint itself, is using that litigation to increase access to PrEP. That lawsuit is ongoing.

U.S. taxpayers have invested over $2.5 billion in the development of mRNA-1273. Now it is time for our government to ensure that this critical lifesaving technology be made available to all. This could contribute to saving millions of lives globally. It also will help protect public health here at home. Global vaccination with highly effective vaccines, like mRNA-1273, is our best defense against the development of vaccine-resistant variants of SARS-CoV2.

Thank you.


Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.

This is the world we live in. This is the world we cover.

Because of people like you, another world is possible. There are many battles to be won, but we will battle them together—all of us. Common Dreams is not your normal news site. We don't survive on clicks. We don't want advertising dollars. We want the world to be a better place. But we can't do it alone. It doesn't work that way. We need you. If you can help today—because every gift of every size matters—please do. Without Your Support We Simply Don't Exist.

'Political Malpractice': House Democrats' Bill Wouldn't Add Dental to Medicare Until 2028

"I don't want to see it drawn out to as far as the House has proposed," Sen. Bernie Sanders said during a recent press call.

Jake Johnson ·


'How Many More Deaths Must It Take?' Barbados Leader Rips Rich Nations in Fierce UN Speech

"How many more variants of Covid-19 must arrive, how many more, before a worldwide plan for vaccinations will be implemented?"

Jake Johnson ·


To Avert Debt Ceiling Calamity, Democrats Urged to Finally Kill the Filibuster

"The solution is to blow up the filibuster at least for debt limit votes, just as Mitch blew it up to pack the Supreme Court for his big donors."

Jake Johnson ·


Biden Decries 'Outrageous' Treatment of Haitians at Border—But Keeps Deporting Them

"I'm glad to see President Biden speak out about the mistreatment of Haitian asylum-seekers. But his administration's use of Title 42 to deny them the right to make an asylum claim is a much bigger issue."

Jessica Corbett ·


Global Peace Activists Warn of Dangers of US-Led Anti-China Pacts

"No to military alliances and preparation for catastrophic wars," anti-war campaigners from over a dozen nations write in a letter decrying the new AUKUS agreement. "Yes to peace, disarmament, justice, and the climate."

Brett Wilkins ·

Support our work.

We are independent, non-profit, advertising-free and 100% reader supported.

Subscribe to our newsletter.

Quality journalism. Progressive values.
Direct to your inbox.

Subscribe to our Newsletter.


Common Dreams, Inc. Founded 1997. Registered 501(c3) Non-Profit | Privacy Policy
Common Dreams Logo